Cell Source, Inc.

OTC: CLCS · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001569340Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 38

v0.1 · 5/100 weight · pillars only

↑ market scale, listing tenure · ↓ workforce scale, balance-sheet leverage

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$4.5M

Employees

as of 2026-08-20

Market cap

$44.0M

as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$4.5M-$4.5M2024

Operating income-$3.8M-$3.8M2024

Total assets$286.5k$286.5k2024

Liabilities$18.8M$18.8M2024

Equity-$18.5M-$18.5M2024

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Cell Source, Inc.’s financial profile?

Cell Source, Inc. earned -$4.5M in FY2024 net income.

Peers · Healthcare

Mach7 Technologies Limited——Vicapsys Life Sciences, Inc.——Context Therapeutics Inc.——Rocket Doctor AI Inc.——BetterLife Pharma Inc.——BriaCell Therapeutics Corp.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOItamar Shimrat

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeOTC: CLCS

Employees1

IPO date2014-05-01

Latest filings

10-Q2026-05-14 10-K2026-04-07 8-K2025-06-27 10-Q2024-11-14 10-Q2024-08-19 10-Q2024-07-29 10-K2024-06-24 8-K2024-04-09

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.